| Company Name: |
cjbscvictory |
| Tel: |
13348960310 13348960310 |
| Email: |
3003867561@qq.com |
SRT3657 manufacturers
- SRT3657
-
- $3400.00
-
2026-05-11
- CAS:1383551-17-4
- Purity:
- Supply Ability: 10g
- SRT3657
-
- $3400.00
-
2025-08-22
- CAS:1383551-17-4
- Purity:
- Supply Ability: 10g
|
| | SRT3657 Basic information |
| Product Name: | SRT3657 | | Synonyms: | SRT3657;SRT3657,SRT-3657;1-Piperidinecarboxylic acid, 4-[[2-[2-[[[2-butyl-6-[[2-[[(1,1-dimethylethoxy)carbonyl]methylamino]ethyl]amino]-4-pyrimidinyl]carbonyl]amino]phenyl]thiazolo[5,4-b]pyridin-6-yl]methoxy]-, 1,1-dimethylethyl ester | | CAS: | 1383551-17-4 | | MF: | C40H54N8O6S | | MW: | 774.97 | | EINECS: | | | Product Categories: | | | Mol File: | 1383551-17-4.mol |  |
| | SRT3657 Chemical Properties |
| density | 1.27±0.1 g/cm3(Predicted) | | pka | 9.85±0.70(Predicted) |
| | SRT3657 Usage And Synthesis |
| Uses | SRT3657 is a brain-permeable activator of SIRT1, with neuroprotective effect[1]. | | in vivo | SRT3657 (30 mg/kg; i.g.; daily; for 6 weeks) activates SIRT1 in CK-p25 mice[1].
SRT3657 treatment prevents synaptic and neuronal loss and effectively rescues against neurodegeneration-driven memory impairments[1].
SRT3657 recapitulates the neuroprotective potential of caloric restriction (CR)[1].
| Animal Model: | Adult double-transgenic CK-p25 mice (3-month-old)[1] | | Dosage: | 30 mg/kg | | Administration: | Oral gavage, daily, for 6 weeks | | Result: | Significantly upregulated the activity of SIRT1 in hippocampal extracts of CK-p25 animals. |
| | References | [1] Grff J, et al. A dietary regimen of caloric restriction or pharmacological activation of SIRT1 to delay the onset of neurodegeneration. J Neurosci. 2013 May 22;33(21):8951-60. DOI:10.1523/JNEUROSCI.5657-12.2013 |
| | SRT3657 Preparation Products And Raw materials |
|